Clinical Trials & Research Studies
Breast cancer clinical trials, also called clinical studies, are a type of research study that tests how well new medical approaches work in people. These studies test new methods of screening, prevention, diagnosis or treatment.
In this section, get basic information about metastatic breast cancer clinical trials, explore whether taking part in a clinical trial is right for you and find studies you may be eligible to participate in.
You can also get information and updates on other breast cancer research studies that follow participants over time to determine treatment outcomes.
The phase II HERMIONE study is designed to compare MM-302, a new anti-HER2 medicine, plus trastuzumab, to chemotherapy of a physician’s choice, plus trastuzumab.
Researchers seek 600 men or postmenopausal women who have hormone receptor-positive, HER2-negative breast cancer that has spread to tissue, lymph nodes or another area of the body for a phase III study.
Researchers seek 500 women who have hormone receptor-positive, HER2-negative advanced breast cancer to take part in a phase III study testing a new medicine pair. Women who are postmenopausal, or no longer get their periods, may qualify to enroll in the study if they have not yet received treatment for advanced breast cancer.
A study designed to learn more about uncertainty, perceived threat, stress, positive appraisal and daily spiritual experiences in women with breast cancer or a history of breast cancer is actively recruiting.
Researchers seek 880 men and women with metastatic breast cancer who have a primary tumor still in the breast for a study designed to find out if removing it lengthens survival. The primary tumor is the first tumor in the breast. Cancer cells from the primary tumor can spread to other parts of the body, causing metastatic disease.
The BROCADE study needs men and women with metastatic breast cancer and a BRCA1 or BRCA2 gene mutation for a phase II clinical trial. The trial team will assess how safe and effective a new targeted therapy is when combined with one or more common chemotherapy medicines.
Researchers seek 240 women with metastatic, triple-negative breast cancer for a phase II study assessing the safety of different chemotherapy combinations and how well they prevent the worsening of the disease.
The Step by Step research study is recruiting women affected by breast cancer for a free, 12-week walking program facilitated online.
Postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that continued to grow during or after treatment with an aromatase inhibitor (anastrozole, letrozole, and exemestane) are needed for a clinical trial. Researchers conducting the trial are examining the safety and effectiveness of combining the PI3K inhibitor BMK120 with fulvestrant (Faslodex).
The Dr. Susan Love Research Foundation and the Beck Research Institute at City of Hope created a one-of-a-kind online study to examine breast cancer causes, treatment and prevention.
Baltimore-based researchers seek participants with metastatic breast cancer for a phase II trial comparing a combination of chemotherapy plus a cancer vaccine with or without trastuzumab.
Researchers seek women with metastatic, HER2 positive breast cancer for a clinical trial that will test a new combination treatment.
Researchers seek women with ER positive, HER2 negative metastatic breast cancer for a clinical trial that will test letrozole in combination with a new medicine.
A clinical trial seeks 880 participants to test whether removing the tumor in the breast in newly diagnosed metastatic breast cancer helps women who receive systemic therapy to live longer than those who receive systemic therapy alone.